Table 1.
Baseline characteristics of the trials included in the network meta-analysis.
| Author | Year | mean HbA1c | FBG(mmol/L) | Number | Male (%) | Age (year) | BMI(kg/m2) | Experimental group | Control group | Duration |
|---|---|---|---|---|---|---|---|---|---|---|
| Sposito (30) | 2021 | 7.9 ± 0.9 | 9.67 ± 2.4 | 48,49 | 29,30 | 57.0 ± 7.0 | 31.0 ± 4.0 | dapagliflozin | glibenclamide | 12 weeks |
| Zainordin (31) | 2019 | 9.7 ± 1.9 | 10.69 ± 4.6 | 36,36 | 28,27 | 57.3 ± 8.5 | 27.5 ± 4.1 | dapagliflozin | placebo | 12 weeks |
| Shigiyama (32) | 2017 | 6.8 ± 0.5 | 7.42 ± 1.5 | 37,37 | 25,22 | 57.9 ± 8.3 | 26.8 ± 4.6 | dapagliflozin | Metformin | 16 weeks |
| Sakai-A (33) | 2019 | 6.8 ± 1.2 | 8.47 ± 1.7 | 59,63 | 36,27 | 62.0 ± 9.4 | 27.5 ± 7.9 | empagliflozin | luseogliflozin | 12 weeks |
| Sakai-B (33) | 2019 | 6.8 ± 1.2 | 8.47 ± 1.7 | 59,62 | 36,49 | 62.0 ± 9.4 | 27.5 ± 7.9 | empagliflozin | tofogliflozin | 12 weeks |
| Sakai-C (33) | 2019 | 6.8 ± 1.2 | 8.47 ± 1.7 | 63,62 | 27,49 | 62.0 ± 9.4 | 27.5 ± 7.9 | luseogliflozin | tofogliflozin | 12 weeks |
| Irace (34) | 2020 | 8.4 ± 0.7 | 10.30 ± 3.1 | 20,15 | 15,12 | 58.0 ± 9.0 | 30.0 ± 4.0 | empagliflozin | Incretin | 3 months |
| Solini (35) | 2017 | NA | 7.96 ± 2.5 | 16,10 | 11,7 | 57.0 ± 9.0 | 30.5 ± 6.7 | dapagliflozin | hydrochlorothiazide | 2 days |
| Solini (36) | 2019 | 7.5 ± 0.5 | 8.16 ± 2.0 | 20,20 | 12,14 | 60.0 ± 8.0 | 32.4 ± 6.7 | dapagliflozin | hydrochlorothiazide | 4 weeks |
| Ikonomidis (37) | 2020 | 7.8 ± 0.9 | 8.06 ± 1.8 | 40,40 | 30,27 | 58.0 ± 10.0 | 29.8 ± 3.0 | SGLT‐2 | GLP‐1 | 12 months |
| Ramirez (38) | 2019 | 8.1 ± 0.5 | 8.67 ± 0.6 | 15,15 | 8,8 | 63.0 ± 8.0 | NA | Canagliflozin | Perindopril | 6 months |
| Striepe (39) | 2017 | 6.8 ± 0.8 | NA | 38,38 | 21,21 | 62.0 ± 7.0 | NA | empagliflozin | placebo | 6 weeks |
| Katakami (40) | 2021 | 7.5 ± 0.7 | 8.00 ± 1.8 | 80,74 | 48,48 | 61.5 ± 9.2 | 26.4 ± 5.4 | tofogliflozin | conventional | 104 weeks |
FBG, fasting blood-glucose; NA: not available.